

Oncology company Beta Drugs raises Rs 117 Cr from HealthQuad and others to accelerate growth plans

27 November 2024 | News

Beta Drugs has expanded its footprint to over 46 countries



Beta Drugs, a leading vertically integrated oncology focused formulations company in Himachal Pradesh, has raised primary capital worth Rs 117 crore from HealthQuad Fund II, and other investors including a Singapore-based investment fund and a private wealth management firm for a minority stake in the Company.

As one of the few vertically integrated manufacturers in the country, Beta Drugs has established a robust position within the country and has also expanded its footprint to over 46 countries, holding accreditations from regulatory bodies such as ANVISA Brazil, INVIMA, PICS, and EAEU.

HealthQuad is India's largest healthcare transformation fund that backs innovative models to radically improve healthcare access, affordability, and quality of care.

Rahul Batra, Chairman & Managing Director of Beta Drugs said, "HealthQuad's investment and expertise will play a pivotal role in accelerating our growth journey, as we strive to position ourselves among the top five oncology companies in India over the next five years. By leveraging HealthQuad's global network and deep knowledge of the pharmaceutical industry, we are confident in our ability to drive innovation, expand our reach, and enhance patient care."

Ajay Mahipal, Partner at HealthQuad Capital said, "HealthQuad has a strong focus on improving healthcare outcomes,

especially for the underserved communities and has a positive outlook towards the future of curative oncology in India, which is echoed in Beta Drugs' mission. Beta Drugs, with its strong manufacturing and R&D capabilities, is poised to improve affordability in the middle- and lower-income segment, and accessibility in tier II and tier III cities in the country. We believe in the transformative potential of their new product launches, expanding export markets, and experienced management team, all of which position the company for substantial growth and value creation."